Individuals who were a part of the investigators Screen-HF study (NCT00400257) whose BNP level are in the top quintile will be offered participation in this study. Participants will be randomised to receive either spironolactone or placebo for three years. Participants will then be monitored for indications of heart failure. It is anticipated that the medication will reduce the development of heart failure in this group.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
20
25 mg tablets (placed in capsules for blinding) once daily.
Placebo (lactose in capsules for blinding) once daily
Alfred Hospital
Melbourne, Victoria, Australia
Effectiveness of Spironolactone in preventing heart failure
Time frame: 1 year and 3 year
Cost effectiveness of Spironolactone prevention
Time frame: 3 years
Development of evidence of LV dysfunction, either systolic or diastolic, on echocardiography and/or symptomatic heart failure
Time frame: 1 year and 3 year
Change in 6 minute walk test between the two groups
Time frame: 1 year and 3 years
Change in quality of life between the two groups
Time frame: 1 year and 3 year
Change in left ventricular remodelling parameters
Time frame: 1 year and 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.